UK MHRA Guidance: Medicines – Apply for a Variation to Your Marketing Authorisation

Marketing Authorisations (MAs) require updates throughout a medicine's lifecycle to reflect changes in manufacturing, quality, safety, efficacy, product information, or administrative details. To ensure that these changes are appropriately assessed and approved while maintaining product quality and patient safety, the Medicines and Healthcare products Regulatory Agency (MHRA) provides detailed guidance on applying for variations to UK Marketing Authorisations.

The MHRA guidance, Medicines: Apply for a Variation to Your Marketing Authorisation, outlines the procedures for submitting minor and major variations, extension applications, revised product information, and grouped submissions. It also explains variation classifications, submission requirements, common validation issues, and special procedures applicable to Northern Ireland and COVID-19 vaccines, helping Marketing Authorisation Holders (MAHs) manage post-authorisation changes efficiently.

Why This Guidance Is Important

Following the approval of a medicine, changes are often required to accommodate manufacturing improvements, regulatory updates, safety information, product information revisions, or business-related modifications. Every proposed change must be classified correctly and submitted through the appropriate regulatory pathway to ensure continued compliance with UK legislation.

Marketing Authorisation Types

The guidance applies to different types of UK Marketing Authorisations, including national licences and other authorisations managed under UK medicines legislation. Marketing Authorisation Holders should identify the appropriate authorisation before preparing any variation application, as submission procedures and regulatory requirements may differ depending on the type of licence involved.

UK Variation Procedures

The MHRA provides several regulatory procedures to manage post-authorisation changes based on the nature and impact of the proposed modification.

Applications should be submitted using the appropriate variation procedure, ensuring that supporting documentation is complete and consistent with the proposed change. Selecting the correct procedure helps facilitate efficient regulatory assessment while maintaining compliance throughout the product lifecycle.

UK Variation Classification

Every proposed change must first be classified according to its regulatory impact. The guidance categorises variations into minor variations (Type IA and Type IB), major variations (Type II), and extension applications.

Correct classification is essential because it determines the level of supporting data required, the assessment procedure, applicable timelines, and regulatory fees. Marketing Authorisation Holders are encouraged to carefully evaluate proposed changes before submission to avoid invalid applications.

Minor Variations (Type IA and Type IB)

Minor variations are intended for changes that have little or no significant impact on the quality, safety, or efficacy of the medicinal product.

Type IA variations generally involve straightforward administrative or technical updates that may be implemented with minimal regulatory assessment, while Type IB variations require MHRA review before implementation where the impact of the change requires additional evaluation.

Applicants should ensure that all supporting documentation is complete and accurately reflects the proposed variation.

Major Variations (Type II)

Type II variations apply to significant changes that may affect the quality, safety, or efficacy of an authorised medicine.

These variations require a comprehensive scientific assessment by the MHRA and are commonly used for substantial manufacturing changes, updates supported by new clinical or non-clinical data, significant product information revisions, and other major modifications requiring regulatory approval before implementation.

Common Invalidation Errors and Pre-Submission Checklist

Incomplete applications remain one of the most common causes of regulatory delays. The MHRA encourages applicants to verify that the correct variation category has been selected, all required documentation has been included, application forms are completed accurately, supporting data are provided where required, and product information is consistent throughout the submission.

Careful use of the pre-submission checklist can significantly reduce validation issues and improve assessment timelines.

Extension Applications

Certain proposed changes are considered so significant that they cannot be managed through the variation procedure and instead require an extension application.

Extension applications are generally required where changes result in a fundamentally different medicinal product, such as the introduction of a new pharmaceutical form, strength, or route of administration. These applications undergo a separate regulatory assessment before approval.

Revised Labels, Leaflets and Packaging

Where a variation results in changes to product information, Marketing Authorisation Holders must also submit updated labels, Patient Information Leaflets (PILs), and packaging artwork where applicable.

These materials should accurately reflect the approved variation while remaining compliant with current MHRA labelling and packaging requirements.

Submitting Multiple Changes

The guidance allows multiple related changes to be submitted together where appropriate. Grouping eligible variations into a single submission can improve regulatory efficiency, reduce administrative burden, and simplify lifecycle management.

Applicants should ensure that grouped variations satisfy MHRA eligibility requirements before submission.

Bulk Submissions and Composite Coordination Collection (CCC)

For organisations managing multiple Marketing Authorisations, the MHRA provides mechanisms for submitting the same variation across several products through bulk submissions where applicable.

The guidance also explains the Composite Coordination Collection (CCC) procedure, which facilitates coordinated assessment of eligible related submissions, improving consistency and regulatory efficiency across product portfolios.

Northern Ireland Considerations

Where Northern Ireland is a Concerned Member State, additional regulatory procedures may apply depending on the type of Marketing Authorisation and the proposed variation.

Applicants should carefully consider the relevant regulatory requirements when preparing submissions that involve Northern Ireland to ensure continued compliance with applicable legislation.

Fees and Submission Process

Variation applications are subject to MHRA fees based on the type of submission being made. Applicants should confirm the applicable fee before submission and ensure that all required documentation is provided electronically using the appropriate MHRA submission process.

Following the correct application procedure and submitting complete documentation helps minimise validation issues and supports timely regulatory review.

The MHRA guidance on applying for variations to a Marketing Authorisation provides a comprehensive framework for managing post-authorisation changes throughout a medicine's lifecycle.

References

• For complete details, refer to: Medicines: Apply for a Variation to Your Marketing Authorisation